CD44/JAK2/STAT3 signaling pathway
The CD44/JAK2/STAT3 signaling pathway is a cell-Signaling axis centered on the transmembrane adhesion receptor CD44 and the intracellular kinases/transcription factors JAK2 and signal transducer and activator of transcription 3 (STAT3).
The CD44/JAK2/STAT3 signaling pathway is a cell-Signaling axis centered on the transmembrane adhesion receptor CD44 and the intracellular kinases/transcription factors JAK2 and signal transducer and activator of transcription 3 (STAT3). In biomedical research, this pathway is commonly discussed as a regulator of cell survival, proliferation, inflammatory signaling, stem-like phenotypes, immune-cell polarization, and tumor progression. CD44 is frequently implicated in hyaluronan-dependent cell interactions and tumor microenvironment signaling, while JAK2-mediated phosphorylation of Signal Transducer and Activator of Transcription 3 (STAT3) can drive transcriptional programs associated with inflammation and malignancy.
In recent literature, this pathway has been studied in cancer and inflammatory disease contexts, including thyroid cancer, pancreatic cancer, glioblastoma, acute myeloid leukemia, acute lymphoblastic leukemia, psoriasis, cutaneous T-cell lymphoma, and acute lung injury. It also appears in mechanistic studies of natural products and combination therapies that modulate IL-6/JAK2/signal transducer and activator of transcription 3 (STAT3), JAK2/signal transducer and activator of transcription 3 (STAT3), or CD44-linked signaling, often alongside related pathways such as PI3K/Akt signaling pathway, PI3K/AKT/mTOR pathway, TGFB1, Interleukin-6 (IL-6), KRAS, and STAT5A.
Where the papers sit
11 papers from the last 6 months study CD44/JAK2/STAT3 signaling pathway directly · updated from PubMed 12 Oct 2026
Study type 1 clinical trial · 10 preclinical
Themes no clear themes · 1 paradigm shift · 1 new direction
Those 11 do not share a common subject.
-
Cancer therapies, inflammatory disorders, infection-related immunosuppression, and drug-safety assessment appear without a shared mechanistic question. Cancer studies test targeted combinations, immunotherapy, nanoparticles, and EGFR/JAK2/STAT3 inhibition, while inflammatory studies focus on STAT3/NF-κB or Th17 modulation. Evidence ranges from cell lines and animals to a QT study, so no consistent therapeutic direction emerges. The cluster is best treated as a heterogeneous collection rather than a developing research program.
Durable treatment cannot rely on STAT3 blockade as an isolated therapeutic intervention
The fungal-metabolite immunotherapy study in tumor-associated macrophages and the multi-node targeted therapy study in orthotopic pancreatic ductal adenocarcinoma independently point beyond single-axis STAT3 inhibition: IM502 overcomes immunosuppression and PD-1-blockade resistance by inhibiting PI3Kγ and redirecting signaling from STAT3/6 toward STAT1/2, whereas combined KRAS, EGFR-family, and STAT3 inhibition produces complete tumor regression without resistance 42173096May 42224594Jun. The resulting change is to treat STAT3-associated resistance as a network or state problem requiring signaling reprogramming or simultaneous blockade of parallel dependencies, rather than as a defect that can reliably be solved by suppressing STAT3 alone.
CD44 can act as a glycan-dependent antibody decoy that physically limits target access
The chondroitinase ABC study in pancreatic ductal adenocarcinoma assigns CD44 a role not represented by the set’s CD44-targeted delivery systems: CD44 was identified as a core protein of chondroitin sulfate A-bearing proteoglycans that mask HER2, while the CS-A chains also bind trastuzumab and inhibit its engagement with HER2 42001719Apr. This extends CD44 from a targeting receptor or signaling-associated molecule to a structural mediator of antibody resistance, suggesting that enzymatic removal of CD44-associated glycans may restore antibody access where drug loading or receptor-directed delivery alone does not.
Papers
The 11 papers from the last 6 months that study CD44/JAK2/STAT3 signaling pathway directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
No clear themes (11)
- Novel patient-derived tongue squamous cell carcinoma cell lines from non-smokers: 3D and in vivo models for drug response studies. Medical oncology (Northwood, London, England) · 29 Jun 2026 PMID 42371352
- Moxibustion combined with anti-PD-1 antibodies improves immunosuppression in septic mice potentially through the PD-1/PD-L1 pathway. Immunologic research · 17 Jun 2026 PMID 42307810
- A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. Proceedings of the National Academy of Sciences of the United States of America · 1 Jun 2026 PMID 42224594
- Pacritinib Impact on QT Interval: Results of a Thorough QT Study and Post Hoc Analysis of Prospective Clinical Trial Data. Clinical pharmacology in drug development · 29 May 2026 PMID 42213484
- Fungal metabolite-based immunotherapy overcomes tumor-associated macrophage immunosuppression. Cell reports. Medicine · 22 May 2026 PMID 42173096
- Targeted dermal delivery of phloretin via thermoresponsive nanoparticles potently suppresses STAT3/NF-κB-driven psoriatic inflammation. Phytomedicine : international journal of phytotherapy and phytopharmacology · 14 May 2026 PMID 42134228
- A mechanistic study on the SIRT3/RORγt/STAT3-regulated Th17-targeted bionic black phosphorus quantum dot cluster nanozyme for improving sepsis-associated acute kidney injury. Biomaterials science · 7 May 2026 PMID 42093466
- Preparation of CPD12C15 hyaluronic acid nanoparticles, a novel glycolytic inhibitor and preliminary pharmacologic study on anti-pancreatic cancer. International journal of pharmaceutics · 29 Apr 2026 PMID 42055152
- 3-Deoxy-4-sulfonamido-butein derivatives promote cell cycle arrest and apoptosis by inhibiting EGFR/JAK2/STAT3 signaling in A549 lung cancer cells. Bioorganic & medicinal chemistry · 27 Apr 2026 PMID 42044554
- Superior In Vivo Efficacy of Fermented Over Aqueous Astragalus membranaceus in Diabetic Nephropathy: A Systematic Pharmacological Evaluation and Mechanistic Study. Biomedical chromatography : BMC · 20 Apr 2026 PMID 42009593
- Chondroitinase ABC enhances trastuzumab activity via cell-surface chondroitin sulfate cleavage in pancreatic cancer cells. Biochemical and biophysical research communications · 19 Apr 2026 PMID 42001719
By study type
Clinical trials (1)
- Pacritinib Impact on QT Interval: Results of a Thorough QT Study and Post Hoc Analysis of Prospective Clinical Trial Data. Clinical pharmacology in drug development · 29 May 2026 PMID 42213484
Preclinical: animal, cell and lab studies (10)
- Novel patient-derived tongue squamous cell carcinoma cell lines from non-smokers: 3D and in vivo models for drug response studies. Medical oncology (Northwood, London, England) · 29 Jun 2026 PMID 42371352
- Moxibustion combined with anti-PD-1 antibodies improves immunosuppression in septic mice potentially through the PD-1/PD-L1 pathway. Immunologic research · 17 Jun 2026 PMID 42307810
- A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. Proceedings of the National Academy of Sciences of the United States of America · 1 Jun 2026 PMID 42224594
- Fungal metabolite-based immunotherapy overcomes tumor-associated macrophage immunosuppression. Cell reports. Medicine · 22 May 2026 PMID 42173096
- Targeted dermal delivery of phloretin via thermoresponsive nanoparticles potently suppresses STAT3/NF-κB-driven psoriatic inflammation. Phytomedicine : international journal of phytotherapy and phytopharmacology · 14 May 2026 PMID 42134228
- A mechanistic study on the SIRT3/RORγt/STAT3-regulated Th17-targeted bionic black phosphorus quantum dot cluster nanozyme for improving sepsis-associated acute kidney injury. Biomaterials science · 7 May 2026 PMID 42093466
- Preparation of CPD12C15 hyaluronic acid nanoparticles, a novel glycolytic inhibitor and preliminary pharmacologic study on anti-pancreatic cancer. International journal of pharmaceutics · 29 Apr 2026 PMID 42055152
- 3-Deoxy-4-sulfonamido-butein derivatives promote cell cycle arrest and apoptosis by inhibiting EGFR/JAK2/STAT3 signaling in A549 lung cancer cells. Bioorganic & medicinal chemistry · 27 Apr 2026 PMID 42044554
- Superior In Vivo Efficacy of Fermented Over Aqueous Astragalus membranaceus in Diabetic Nephropathy: A Systematic Pharmacological Evaluation and Mechanistic Study. Biomedical chromatography : BMC · 20 Apr 2026 PMID 42009593
- Chondroitinase ABC enhances trastuzumab activity via cell-surface chondroitin sulfate cleavage in pancreatic cancer cells. Biochemical and biophysical research communications · 19 Apr 2026 PMID 42001719
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.